

**EQUITY INTEREST/BUSINESS PARTICIPATION SUBMISSION FORM  
REGENTS POLICY 407**

This form is to be submitted with any Board of Regents item when a campus seeks the approval of an agreement with or arrangement regarding an employee pursuant to 20-25-109 MCA and Regents Policy 407.

If any submission concerns matters of trade secrets or confidential business information, or any other matter entitled to privacy under state or federal law (e.g., the federal statute known as Bayh/Dole) the submitting campus may request consideration of the submission, in whole or in part, in executive session.

1. a. Name(s) of the university employee(s) involved.

Michele Hardy, Ph.D, Associate Professor, Veterinary Molecular Biology.

- b. Name(s) of business entity(ies) involved and its contractual relationship with the university or other public agency.

LigoCyte Pharmaceuticals, Inc.

LigoCyte is negotiating to license the intellectual property described below.

2. Summarize the nature of the intellectual property that was developed by the employee seeking approval

Hardy developed Snow Mountain norovirus technology that has the potential to be used in a norovirus vaccine. The Center for Disease Control has recently estimated that noroviruses infect 23 million people annually in the U.S. Infections with noroviruses cause epidemics in closed community settings such as nursing homes, schools, daycare centers, hospitals, and military settings.

3. The university and employee(s) are seeking approval for (check as many as appropriate):

a. The employee has or will be awarded equity interest in the Business Entity.

b. The employee who is serving or may serve as a member of the board of directors or other governing board of the business entity.

c. The employee to accept employment from the Business Entity.

4. How will approval of this relationship contribute to the objectives of the university's technology transfer and intellectual property development programs?

LigoCyte wishes to develop and commercialize the Snow Mountain norovirus technology for use in a norovirus vaccine. LigoCyte is a growing Montana-based company which has provided local economic development, including jobs for Montana students. Hardy has received equity compensation for work for LigoCyte in the past. This approval will facilitate the transfer of useful MSU-developed technology into the larger community.